Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNAO1 | P09471 | 13/20 | 0.61 |
| ▸ | GNAI3 | P08754 | 12/20 | 0.56 |
| ▸ | GNAI1 | P63096 | 12/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.43 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.43 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9383358 | 1.00 | GNAO1 (0.61) | GNAO1GNAI3GNAI1CYP1A2EPHX1 | |
| SCHEMBL9388856 | 1.00 | GNAO1 (0.61) | GNAO1GNAI3GNAI1CYP1A2EPHX1 | |
| SCHEMBL9384220 | 1.00 | GNAO1 (0.61) | GNAO1GNAI3GNAI1CYP1A2EPHX1 | |
| SCHEMBL9385204 | 1.00 | GNAO1 (0.61) | GNAO1GNAI3GNAI1CYP1A2EPHX1 | |
| SCHEMBL9389331 | 1.00 | GNAO1 (0.61) | GNAO1GNAI3GNAI1CYP1A2EPHX1 | |
| SCHEMBL9388213 | 1.00 | GNAO1 (0.61) | GNAO1GNAI3GNAI1CYP1A2EPHX1 | |
| SCHEMBL5494333 | 1.00 | GNAO1 (0.61) | GNAO1GNAI3GNAI1CYP1A2EPHX1 | |
| Hydrochloric Acid SCHEMBL26090986 | 0.98 | GNAO1 (0.64) | GNAO1GNAI3GNAI1CYP1A2EPHX1 | |
| SCHEMBL1368752 | 0.98 | GNAO1 (0.58) | GNAO1GNAI3GNAI1CYP1A2EPHX1 | |
| Hydrochloric Acid SCHEMBL7645440 | 0.95 | GNAO1 (0.61) | GNAO1GNAI3GNAI1CYP1A2ITGB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119799167-A | Chemical mechanical polishing liquid for silicon wafer, preparation method and application | 万华化学集团股份有限公司 | 2025-04-11 | — | — | CN | claimed |
| US-5484949-A | Method for the synthesis of α β-unsaturated ketones | NIPPON SODA CO., LTD. (JP) | 1996-01-16 | — | — | US | claimed |
| CN-119799167-A | Chemical mechanical polishing liquid for silicon wafer, preparation method and application | 万华化学集团股份有限公司 | 2025-04-11 | — | — | CN | disclosed |
| US-20230357180-A1 | DEGRADERS AND DEGRONS FOR TARGETED PROTEIN DEGRADATION | C4 THERAPEUTICS, INC. (US) | 2023-11-09 | — | — | US | disclosed |
| WO-2023067273-A1 | CYCLIC AMINE MONOAMIDES FOR THE EXTRACTION OF URANIUM(VI) AND PLUTONIUM(IV) AND FOR THE SEPARATION THEREOF WITHOUT REDUCTION OF THE PLUTONIUM(IV) | COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) | 2023-04-27 | — | — | WO | disclosed |
| US-20090325923-A1 | NEW METHOD FOR THE TREATMENT OF INFLAMMATORY DISEASES | TOPOTARGET SWITZERLAND SA (CH) | 2009-12-31 | — | — | US | disclosed |
| US-20090325923-A1 | NEW METHOD FOR THE TREATMENT OF INFLAMMATORY DISEASES | TOPOTARGET SWITZERLAND SA (CH) | 2009-12-31 | — | — | US | disclosed |
| US-20070219197-A1 | Pyridyl alkene and pyridyl alkine- acid amides as cytostatics and immuno-suppressives | ASTELLAS PHARMA GMBH (DE) | 2007-09-20 | — | — | US | disclosed |
| US-20070219197-A1 | Pyridyl alkene and pyridyl alkine- acid amides as cytostatics and immuno-suppressives | ASTELLAS PHARMA GMBH (DE) | 2007-09-20 | — | — | US | disclosed |
| US-7241745-B2 | Pyridyl alkene and pyridyl alkine acid amides as cytostatics and immunosupressives | ASTELLAS PHARMA GMBH (DE) | 2007-07-10 | — | — | US | disclosed |
| US-7241745-B2 | Pyridyl alkene and pyridyl alkine acid amides as cytostatics and immunosupressives | ASTELLAS PHARMA GMBH (DE) | 2007-07-10 | — | — | US | disclosed |
| EP-0604494-A1 | 5-HT 4? RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1994-07-06 | — | — | EP | disclosed |
| EP-0593923-A1 | Water-insoluble sulfur dyes, their preparation and their use | HOECHST AKTIENGESELLSCHAFT (DE) | 1994-04-27 | — | — | EP | disclosed |
| CN-1022685-C | Hydrofluorene derivatives | OTSUKA PHARMA CO LTD (JP) | 1993-11-10 | — | — | CN | disclosed |
| EP-0560669-A1 | Piperazinyl-and piperidinyl-cyclohexenes and cyclohexanes | Bristol-Myers Squibb Company (US) | 1993-09-15 | — | — | EP | disclosed |
| EP-0546583-A1 | Piperazinyl-and piperidinyl-cyclohexanols | Bristol-Myers Squibb Company (US) | 1993-06-16 | — | — | EP | disclosed |
| EP-0454867-A1 | A METHOD FOR THE SYNTHESIS OF -g(a), -g(b)-UNSATURATED KETONES. | NIPPON SODA CO (JP) | 1991-11-06 | — | — | EP | disclosed |
| WO-1991007370-A1 | A METHOD FOR THE SYNTHESIS OF α, β-UNSATURATED KETONES | NIPPON SODA CO., LTD. (JP) | 1991-05-30 | — | — | WO | disclosed |
| US-4235875-A | ALKYL 1-(HYDROXYALKYL)PIPERIDINES | A.B. FERROSAN (SE) | 1980-11-25 | — | — | US | disclosed |
| US-4028334-A | STABILIZERS FOR POLYMERS | CIBA-GEIGY CORPORATION (US) | 1977-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070219197-A1 | Pyridyl alkene and pyridyl alkine- acid amides as cytostatics and immuno-suppressives | NFATC1, PDCD1, ACIN1 | GNAO1 2964/4885GNAI3 2743/4885GNAI1 2381/4885 |
| US-20230357180-A1 | DEGRADERS AND DEGRONS FOR TARGETED PROTEIN DEGRADATION | STUB1, MDM2, USP30 | GNAO1 3651/4885GNAI3 3676/4885GNAI1 3225/4885 |
| US-20090325923-A1 | NEW METHOD FOR THE TREATMENT OF INFLAMMATORY DISEASES | NAMPT, NNMT, NQO2 | GNAO1 584/4885GNAI3 961/4885GNAI1 722/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.